October 31, 2016 Critical Path Institute and CHDI Foundation, Inc., establish a consortium to expedite approval of Huntington’s disease therapeutics Oct 31, 2016 Critical Path Institute and CHDI Foundation, Inc., establish a consortium to expedite approval of Hunti
October 25, 2016 TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research Oct 25, 2016 TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research TUCSON, Ariz., October 25, 2016 —
October 24, 2016 Advancing Tuberculosis Drug Regimen Development through Innovative Quantitative Translational Pharmacology Methods and Approaches
October 17, 2016 IMI SAFE-T and C-Path PSTC Obtain Regulatory Support for New Liver Safety Biomarkers Oct 17, 2016 IMI SAFE-T and C-Path PSTC Obtain Regulatory Support for New Liver Safety Biomarkers US FDA and EMA Let
October 10, 2016 Critical Path for Parkinson’s Consortium achieves regulatory support in Europe for use of imaging biomarker in Parkinson’s disease clinical trials Oct 10, 2016 Critical Path for Parkinson’s Consortium achieves regulatory support in Europe for use of imaging
September 30, 2016 The International Neonatal Consortium: Collaborating to Advance Regulatory Science for Neonates Turner MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson, LD. “The International Neonatal Consortium Collaborating to Adv
September 12, 2016-September 13, 2016 Applying Regulatory Science to Neonates: Second Annual Scientific Workshop at European Medicines Agency (EMA) Date: September 12-13, 2016 Location: European Medicines Agency, Canary Wharf, London Sponsors: Critical Path Institute and Euro
August 19, 2016 Alzheimer’s disease patient groups derived from a multivariate analysis of cognitive test outcomes in the Coalition Against Major Diseases dataset
July 14, 2016 Presentations from ADPKD Summit 2016: Addressing the need for Clinical Endpoints in ADPKD Critical Path Institute’s John-Michael Sauer presenting on fluid-based biomarkers and how they could be applied to help...